The prognostic role of metformin in patients with endometrial cancer: a retrospective study

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 203, Issue , 2016, Pages 291-296

  Seebacher, Veronika ^a   Bergmeister, Birgit ^a   Grimm, Christoph ^a   Koelbl, Heinz ^a   Reinthaller, Alexander ^a,b   Polterauer, Stephan ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Karl Landsteiner Institute for General Gynecology and Experimental Gynecologic Oncology   (Austria)

Author keywords

Diabetes; Endometrial cancer; Metformin; Obesity; Prognosis

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; AGED; ARTICLE; BODY MASS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DIABETIC PATIENT; ENDOMETRIUM CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OBESITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; ENDOMETRIUM TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

AGED; DIABETES MELLITUS, TYPE 2; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84978272054     PISSN: 03012115     EISSN: 18727654     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2016.06.013     Document Type: Article

References (22)

1. [1] Cantrell, L.A., Zhou, C., Mendivil, A., Malloy, K.M., Gehring, P.A., Bae-Jump, V.L., Metformin is a potent inhibitor of endometrial cancer cell proliferation – implications for a novel treatment strategy. Gynecol Oncol 116 (2010), 92–98.
2. [2] Schuler, K.M., Rambally, B.S., DiFurio, M.J., et al. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med 4:2 (2015), 161–173.
3. [3] Noto, H., Goto, A., Tsujimoto, T., Noda, M., Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE, 7(3), 2012, e33411, 10.1371/journal.pone.0033411.
4. [4] Soffer, D., Shi, J., Chung, J., et al. Metformin and breast and gynecological cancer risk among women with diabetes. BMJ Open Diabetes Res Care, 3(1), 2015, e000049, 10.1136/bmjdrc-2014-000049.eCollection 2015.
5. [5] Ferlay, J., Soerjomataram, I., Ervik, M., et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No.11 [Internet]. 2013, International Agency for Research on Cancer, Lyon, France Available from: http://globocan.iarc.fr [accessed 21.03.15].
6. [6] Renehan, A.G., Tyson, M., Egger, M., Heller, R.F., Zwahlen, M., Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:9612 (2008), 569–578.
7. [7] Trabert, B., Wentzensen, N., Felix, A.S., Yang, H.P., Sherman, M.E., Brinton, L.A., Metabolic syndrome and risk of endometrial cancer in the United States: a study in the SEER-Medicare linked database. Cancer Epidemiol Biomarkers Prev 24:1 (2015), 251–257.
8. [8] Mitsuhashi, A., Kiyokawa, T., Sato, Y., Shozu, M., Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer 120 (2014), 2986–2995.
9. [9] Tabrizi, A.D., Melli, M.S., Forough, M., Ghojazadeh, M., Bidadi, S., Antiproliferative effect of metformin on the endometrium – a clinical trial. Asian Pac J Cancer Prev 15:23 (2014), 10067–10070.
10. [10] Ko, E.M., Walter, P., Jackson, A., et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 132:2 (2014), 438–442.
11. [11] Newadunsky, N.S., Van Arsdale, A., Strickler, H.D., et al. Metformin use and endometrial cancer survival. Gynecol Oncol 132:1 (2014), 236–240.
12. [12] Al Hilli, M.M., Bakkum-Gamez, J.M., Mariani, A., et al. The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts. Gynecol Oncol 140 (2016), 270–276.
13. [13] Ezewuiro, O., Grushko, T.A., Kocherginsky, M., et al. Association of metformin use with outcomes in advanced endometrial cancer treated with chemotherapy. PLOS one, 11(1), 2016, e0147145, 10.1371/journal.pone.0147145.
14. [14] Hall, C., Stone, R.L., Gehlot, A., Zorn, K.K., Burnett, A.F., Use of metformin in obese women with type I endometrial cancer is associated with reduced incidence of cancer recurrence. Int J Gynecol Cancer 26 (2016), 313–317.
15. [15] Creasman, W.T., Odicino, F., Maisonneuve, P., et al. Carcinoma of the corpus uteri. FIGO 6th annual report on the results of treatment in gynecologic cancer. Int J Gynaecol Obstet 95:Suppl. 1 (2006), 105–143.
16. [16] American Joint Committee on Cancer, Corpus Uteri. AJCC Cancer Staging Manual. 7th ed., 2010, Springer, New York, 403.
17. [17] Seebacher, V., Polterauer, S., Grimm, C., et al. The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial. Br J Cancer 16 (2010), 952–956.
18. [18] Mutter, G.L., Lin, M.C., Fitzgerald, J.T., et al. Altered PTEN expression as a diagnostic marker for the earlies endometrial precancers. J Natl Cancer Inst 92 (2000), 924–930.
19. [19] Iglesias, D.A., Yates, M.S., van der Hoeven, D., et al. Another surprise from metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy. Mol Cancer Ther 12:12 (2013), 2847–2856.
20. [20] Lukanova, A., Zeleniuch-Jacquotte, A., Lundin, E., et al. Prediagnostic levels of C-peptide, IGF-1, IGFBP-1, -2 and -3 and risk of endometrial cancer. Int J Cancer 108:2 (2004), 262–268.
21. [21] Sharma, D., Saxena, N.K., Vertino, P.M., Anania, F.A., Leptin prmotes the proliferative response and invasivenenss in human endometrial cancer cells by activating multiple signal-transduction pathways. Endocr Relat Cancer 13 (2006), 629–640.
22. [22] OECD, Prevalence of obesity among men and women, 2012 (or nearest year), in Health at a Glance: Europe 2014. 2014, OECD Publishing, Paris, 10.1787/health_glance_eur-2014-graph51-en.